Form 6-K Anbio Biotechnology For: Apr 27
Tweet
Share
E-mail
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-42526
Anbio Biotechnology
Friedrich-Ebert-Anlage
35-37, 60327
Frankfurt am Main,
Germany
+49 69870039170
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
In connection with the extraordinary general meeting of shareholders of Anbio Biotechnology (the “Company”), attached hereto and incorporated by reference herein are Notice of Meetings of Shareholders and Proxy Statement and Form of Proxy Card.
1
EXHIBIT INDEX
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Anbio Biotechnology | ||
| Date: April 27, 2026 | By: | /s/ Michael Lau |
| Name: | Michael Lau | |
| Title: | Chief Executive Officer | |
3
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anbio Biotechnology (NNNN) has filed mixed shelf
- Ganfeng LiEnergy Debuts at Intersolar Europe 2026, Building a Full-Chain Energy Storage Operations and Service System
- Ethereum Price Prediction: ETH Selloff Sends Meme Buyers Toward AlphaPepe AI Safety Checks
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
